Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients

Purpose This was a phase I/II adoptive T cell trial in 7 locally advanced and metastatic pancreatic cancer patients using 3–8 infusions of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATs) to determine safety, the maximum tolerated dose (MTD), immune responses, time to progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Lum, Lawrence G., Thakur, Archana, Choi, Minsig, Deol, Abhinav, Kondadasula, Vidya, Schalk, Dana, Fields, Kristie, Dufrense, Melissa, Philip, Philip, Dyson, Gregory, Aon, Hussein D., Shields, Anthony F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480816/
https://www.ncbi.nlm.nih.gov/pubmed/32939319
http://dx.doi.org/10.1080/2162402X.2020.1773201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480816/
https://www.ncbi.nlm.nih.gov/pubmed/32939319
http://dx.doi.org/10.1080/2162402X.2020.1773201

Ejemplares similares